Acetyl-CoA carboxylase beta (ACACB) is a novel metabolism-related biomarker in cancer research. Nowadays, Creative Biolabs provides a comprehensive set of ACACB analysis services for global clients.
Background
In mammals, acetyl-CoA carboxylase alpha (ACACA, ACC1) and acetyl-CoA carboxylase beta (ACACB, ACC2) are two members of acetyl-CoA carboxylases (ACCs). ACACA localizes in the cytosol and ACACB contains a hydrophobic N-terminal region that leads ACC2 to attach to the outer membrane of mitochondria. Increased ACACB expression can be found in tissues with active oxidation, such as the skeletal muscle, heart, and other adipose tissues.
The main role of ACACB is to produce malonyl CoA, which is an effective inhibitor of carnitine palmityl transferase and further effectively inhibits the oxidation of fatty acids. In animal experiments, inhibition of ACC2 can increase hepatic fat oxidation, reduce hepatic lipids, and improve hepatic insulin sensitivity in mice with NAFLD.
Fig.1 Role of ACCs in lipid metabolism.1
Services at Creative Biolabs
ACACB can lead to decreased sensitivity to anti-EGFR monoclonal antibody in colorectal cancer, and its mechanism may be related to EGFR phosphorylation. Bioinformatics analysis shows that ACACB, ADH1C, CES1, MGLL, FMO5, and GPT are the hub DEGs, and ACACB is the most important biomarker among them. Armed with rich experience in diagnostics and biomarker analysis, Creative Biolabs provides tailored services for ACACB research use. Our popular services targeting ACACB include but are not limited to the following:
- Functional analysis of ACACB
- Cell viability assay
- Quantitative RT-PCR (qPCR) analysis
- WB analysis
- IHC analysis
Ready to take your biomarker research to the next level? Get in contact with our experts - We are happy to answer any question! Please feel free to contact us for more information.
Reference
- Hong, Hi-Ju, et al. "ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer: ACACB is a biomarker for CTX therapy in metastatic CRC." Acta Biochimica et Biophysica Sinica 54.11 (2022): 1671. Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.